Open AccessBook
Chronic hepatitis B : an update
Naoky C. S. Tsai,Norman Gitlin +1 more
TLDR
A group of experts in this field is assembled to present their expertise in such a level, where the practicing clinicians who deal with this disease in their daily practice can understand thereby implement this knowledge into their own practice.Abstract:
A recent Institute of Medicine report has concluded that 'there is a lack of knowledge and awareness about chronic viral hepatitis on the part of health-care and social-service providers, as well as among at-risk populations, members of the public, and policy-makers. Due to the insufficient understanding about the extent and seriousness of this public-health problem, inadequate public resources are being allocated to prevention, control, and surveillance programs'. It is with these concerns in mind that Dr. Tsai assembled a group of experts in this field to present their expertise in such a level, where the practicing clinicians who deal with this disease in their daily practice can understand thereby implement this knowledge into their own practice. Dr. Brian McMahon discusses the natural history of chronic hepatitis B with his vast knowledge and experience working with the high endemic population of Inuit in Alaska. Drs. Marc Ghany and Ed provide a very easy-to-understand description of HBV virology. Dr. Kyon-Mi Chang contributes an article on HBV immunology, which is the least understood area of this disease but has the most potential to improve our knowledge in the management of chronic hepatitis B. Dr. Anna Lok provides an authoritative review on the current issues and controversies of treatment of chronic hepatitis B. Dr. Stephen Locarnini, who has extensive experience in anti-viral resistance and its management, presents important issues in the usage of currently available anti-viral oral agents. Dr. Myron Tong discusses the current understanding of HBV carcinogenesis and updates HCC surveillance and treatment - the most dreadful outcome of this disease. Dr. Paul Martin discusses management of end- stage chronic hepatitis B - anti-viral therapy, montherapy vs combo therapy, choice of agent, when to start therapy and post-transplant patients including duration of HBIG therapy, HBcAb(+)only recipient) and Occult HBV infection. Dr. Tram Tran discusses the treatment in reproductive women, during pregnancy, and prevention of vertical transmission in third trimester with antiviral agents - an area with significant lack of good clinical evidence. Dr. Steve Han discusses management of patients with acute hepatitis B, co-infection with HDV/HCV/HIV, pre-immuno-suppressive therapy, and management of renal and heart transplant patients with HBV infection. Dr. Mei Huei Chang discusses Taiwanese success in implementing universal vaccination leading to a remarkable reduction in both prevalence of chronic hepatitis B and incidence of hepatocellular carcinoma. Finally Drs. Michelle Lai and Yun Fan Liaw provide a rundown of what we have accomplished and the hope for the future in our fight to control this disease.read more
Citations
More filters
Journal ArticleDOI
Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study.
Phunchai Charatcharoenwitthaya,Wattana Sukeepaisarnjaroen,Teerha Piratvisuth,Satawat Thongsawat,Theeranun Sanpajit,Soonthorn Chonprasertsuk,Woramon Jeamsripong,Ekawee Sripariwuth,Piyawat Komolmit,Tanisa Patcharatrakul,Rattana Boonsirichan,Chalermrat Bunchorntavakul,Supoj Tuntipanichteerakul,Tawesak Tanwandee +13 more
TL;DR: This work investigated the efficacy of peginterferon for CHB and validated the performance of previously identified response predictors in clinical practice.
Journal ArticleDOI
Detectability and clinical significance of serum hepatitis B virus ribonucleic acid.
TL;DR: Serum hepatitis B virus (HBV) RNA is detected during treatment with nucleoside analogue as a consequence of interrupted reverse transcription and unaffected replicative intermediates and correlates better with serum quantitative HBsAg (qHBsAg) than with serum HBV DNA levels.
Journal ArticleDOI
Insights Into the Coinfections of Human Immunodeficiency Virus-Hepatitis B Virus, Human Immunodeficiency Virus-Hepatitis C Virus, and Hepatitis B Virus-Hepatitis C Virus: Prevalence, Risk Factors, Pathogenesis, Diagnosis, and Treatment
Sagarika Shahriar,Yusha Araf,Rasel Ahmad,Pravakar Kattel,Ganga Sagar Sah,Tanjim Ishraq Rahaman,Rahila Zannat Sadiea,S. Sultana,Md. Sayeedul Islam,Chunfu Zheng,Md. Golzar Hossain +10 more
TL;DR: The treatment of coinfected patients is complicated due to the side effects of antiviral medication, resulting in drug resistance, hepatotoxicity, and a lack of required responses, and the diagnosis and treatment is complicated.
Journal ArticleDOI
Real-World Application of the Roadmap Model in Chronic Hepatitis B Patients with Telbivudine Therapy
Hsien-Chung Yu,Kung-Hung Lin,Ping-I Hsu,Feng-Woei Tsay,Huay-Min Wang,Tzung-Jiun Tsai,Kwok-Hung Lai +6 more
TL;DR: Modification of the roadmap model to incorporate early qHBsAg kinetics may further optimize the efficacy of the treatment strategy of hepatitis B virus.
Journal ArticleDOI
Gateway to Care campaign: a public health initiative to reduce the burden of hepatitis B in Haimen City, China
TL;DR: Lessons from the implementation phase of the Haimen City HBV elimination campaign include the importance of gaining early and ongoing support from the local government and health bureau for success in reaching the targeted populations; and having project management by a local, experienced, and trusted health expert to navigate implementation and relationships.